What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
Harold J. Burstein mainly investigates Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer.
His work in Metastatic breast cancer, Adjuvant therapy, Mastectomy, Neoadjuvant therapy and Survival rate are all subfields of Internal medicine research.
His Breast cancer research incorporates themes from Radiation therapy, Randomized controlled trial, Surgery, Guideline and Gynecology.
His Oncology research includes themes of Trastuzumab, MEDLINE, Breast disease, Tamoxifen and Disease.
His work on Lapatinib as part of general Trastuzumab study is frequently connected to Vinorelbine, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His biological study spans a wide range of topics, including Regimen, Clinical trial and Mammary gland.
His most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer (1459 citations)
- Clinical practice guidelines in oncology (1369 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy.
He regularly ties together related areas like Surgery in his Internal medicine studies.
His Oncology research also works with subjects such as
- MEDLINE that connect with fields like Guideline,
- Mastectomy which is related to area like Neoadjuvant therapy.
His study looks at the relationship between Breast cancer and fields such as Disease, as well as how they intersect with chemical problems.
The concepts of his Cancer study are interwoven with issues in Adverse effect, Intensive care medicine, Family medicine and Pathology.
The various areas that he examines in his Trastuzumab study include Regimen, Chemotherapy regimen, Paclitaxel and Anthracycline.
He most often published in these fields:
- Internal medicine (74.05%)
- Oncology (69.10%)
- Breast cancer (64.72%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (74.05%)
- Oncology (69.10%)
- Breast cancer (64.72%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Adjuvant and MEDLINE.
He has researched Oncology in several fields, including Trastuzumab, Early breast cancer, Recurrence score, Palbociclib and Estrogen.
His work carried out in the field of Breast cancer brings together such families of science as Stage and Randomized controlled trial.
His Adjuvant study combines topics from a wide range of disciplines, such as Pharmaceutical Adjuvants, Endocrine therapy and Paclitaxel.
His research investigates the connection between MEDLINE and topics such as Medical physics that intersect with issues in Sunitinib.
His Chemotherapy research integrates issues from Aromatase inhibitor, Tamoxifen, Exemestane and Quality of life.
Between 2016 and 2021, his most popular works were:
- Clinical practice guidelines in oncology (1369 citations)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (494 citations)
- NCCN Guidelines® insights breast cancer, version 1.2017: Featured updates to the NCCN Guidelines (221 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Harold J. Burstein focuses on Breast cancer, Internal medicine, Oncology, Chemotherapy and Randomized controlled trial.
His work on Systemic therapy as part of his general Breast cancer study is frequently connected to Context, thereby bridging the divide between different branches of science.
His work on Cancer, Clinical endpoint, Primary therapy and Stage as part of general Internal medicine study is frequently linked to Watchful waiting, bridging the gap between disciplines.
His work in the fields of Oncology, such as Adjuvant, overlaps with other areas such as Annals.
His Chemotherapy research includes elements of Aromatase inhibitor, Tamoxifen, Exemestane and Quality of life.
Harold J. Burstein has included themes like Survival rate and Clinical trial in his Randomized controlled trial study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
